Literature DB >> 11249569

Macrolide antibiotics as biological response modifiers.

B K Rubin1, J Tamaoki.   

Abstract

Erythromycin was first isolated in the 1950s from a Philippine soil sample, and the derivatives of erythromycin A, called the macrolide antibiotics, have been used as effective antibacterial agents ever since. It has long been suspected that the 14-membered macrolides have immunomodulatory activity as demonstrated by their early use as adjunctive therapy for asthma and their astounding effectiveness for the therapy of diffuse panbronchiolitis. It is now clear, that the macrolides and their cousins, the 15-membered azalides, and perhaps the ketolides, have a broad range of biological response modifying effects on inflammation, tumor cells, airway secretions and host defenses. This review highlights some exciting new data, as well as controversies related to understanding the mechanism of action for these diverse effects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11249569

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  13 in total

Review 1.  [Treatment of not-with cystic fibrosis associated forms bronchiectasis (non-CF bronchiectasis)].

Authors:  J Rademacher; M W Pletz; T Welte
Journal:  Internist (Berl)       Date:  2010-12       Impact factor: 0.743

2.  Clindamycin inhibits nociceptive response by reducing tumor necrosis factor-α and CXCL-1 production and activating opioidergic mechanisms.

Authors:  Felipe F Rodrigues; Marcela I Morais; Ivo S F Melo; Paulo S A Augusto; Marcela M G B Dutra; Sarah O A M Costa; Fábio C Costa; Franciele A Goulart; Alysson V Braga; Márcio M Coelho; Renes R Machado
Journal:  Inflammopharmacology       Date:  2019-11-25       Impact factor: 4.473

Review 3.  Immuno-modulation and anti-inflammatory benefits of antibiotics: the example of tilmicosin.

Authors:  André G Buret
Journal:  Can J Vet Res       Date:  2010-01       Impact factor: 1.310

Review 4.  Mechanisms of action and clinical application of macrolides as immunomodulatory medications.

Authors:  Soichiro Kanoh; Bruce K Rubin
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

5.  Effects of azithromycin on shiga toxin production by Escherichia coli and subsequent host inflammatory response.

Authors:  Tatsuki Ohara; Seiichi Kojio; Ikue Taneike; Saori Nakagawa; Fumio Gondaira; Yukiko Tamura; Fumitake Gejyo; Hui-Min Zhang; Tatsuo Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

6.  Molecular mechanisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells: possible role in the signaling pathway that regulates nuclear factor-kappaB activation.

Authors:  Masashi Desaki; Hitoshi Okazaki; Toshiaki Sunazuka; Satoshi Omura; Kazuhiko Yamamoto; Hajime Takizawa
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

Review 7.  Anti-inflammatory therapies for cystic fibrosis-related lung disease.

Authors:  David P Nichols; Michael W Konstan; James F Chmiel
Journal:  Clin Rev Allergy Immunol       Date:  2008-12       Impact factor: 8.667

Review 8.  International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides.

Authors:  Thomas M File; James S Tan
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  The Value of Macrolide-Based Regimens for Community-Acquired Pneumonia.

Authors:  Alexandra McFarlane; Wendy Sligl
Journal:  Curr Infect Dis Rep       Date:  2015-12       Impact factor: 3.725

Review 10.  Secretion properties, clearance, and therapy in airway disease.

Authors:  Bruce K Rubin
Journal:  Transl Respir Med       Date:  2014-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.